RT Journal Article SR Electronic T1 Effect of Polygenic Score on Alzheimer’s Disease Risk Depends on Age and APOE Status JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.06.20052332 DO 10.1101/2020.04.06.20052332 A1 Fulton-Howard, Brian A1 Goate, Alison M. A1 Adelson, Robert P. A1 Koppel, Jeremy A1 Gordon, Marc L. A1 Alzheimer’s Disease Genetics Consortium A1 Barzilai, Nir A1 Atzmon, Gil A1 Davies, Peter A1 Freudenberg-Hua, Yun YR 2020 UL http://medrxiv.org/content/early/2020/04/08/2020.04.06.20052332.abstract AB Polygenic risk scores (PRS) have the potential to serve as a low-cost, non-invasive screening method for Alzheimer’s disease (AD). However, to what extent age and the Apolipoprotein E-ε4 (APOE4) risk allele influence the effect of PRS is underexplored. In a cohort of 346 superager controls (age ≥ 90 years), 2,930 controls (age 60-89) and 1,760 AD cases, we computed APOE-independent PRS for AD. When using superager controls, subjects with PRS in the top decile had nearly five times greater odds of having AD than subjects in the lowest decile (OR=4.91, P=2.24×10−6). In our cross-sectional cohort, PRS modifies the age of onset for AD among APOE4 carriers, but not among non-carriers. Among APOE4 carriers, PRS in the top decile was associated with a five years earlier AD onset than the lowest decile (70.0 vs 75.0 years; t-test P=2.4×10−5). These findings suggest that APOE-independent genetic risk disproportionally affects younger APOE4 carriers, leading to earlier disease onset, while older controls carry less genetic risk.Competing Interest StatementAMG has consulted for Eisai, Biogen, Pfizer, AbbVie, Cognition Therapeutics and GSK. She also served on the SAB at Denali Therapeutics from 2015-2018. YFH co-owns stock and stock options of Regeneron Pharmaceuticals. All other authors have no interests to declare. None of the authors' institutions have contracts relating to this research through which it or any other organization may stand to gain financially now or in the future.Funding StatementThis work was supported by the National Institutes of Health, National Institute on Aging (NIH-NIA) (ADGC and grant numbers U01 AG032984 and RC2 AG036528). Samples from the National Cell Repository for Alzheimer’s Disease (NCRAD), which receives government support under a cooperative agreement awarded by the NIH-NIA (grant number U24 AG21886), were used in this study. The NACC database is funded by the NIH-NIA (grant number U01 AG016976). Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer’s Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (grant number U24-AG041689-01). In addition, this work was funded by the NIH (grant numbers U01AG052411, U01AG058635, K08AG054727, R01 AG618381, and R01 AG046949), and the Einstein Nathan Shock Center (grant number P30 AG038072). Additional support was provided by the Mildred and Frank Feinberg Family Foundation, the Advancing Women in Science and Medicine Foundation, and the JPB Foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genetic data referred to in the manuscript will be made available in a suitable repository, and is available upon reasonable request made to the corresponding author following peer-reviewed publication of the manuscript.